Prasco Laboratories has signed a marketing and distribution agreement with Eli Lilly to market the authorized generic version of ZYPREXA (olanzapine) tablets and ZYPREXA ZYDIS (olanzapine) orally disintegrating tablets, in the U.S.
Prasco will begin distribution of both products upon the first ANDA entrant into the market. Prasco will market all six strengths of olanzapine tablets. Olanzapine orally disintegrating tablets will be available in four strengths. The financial terms of the agreement were not disclosed.
“Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the olanzapine launch through our new Lilly relationship,” said Prasco chief executive officer E. Thomas Arington.